PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25914645-9	2015	Tetraethylammonium accumulation was higher in SLC22A1-expressing cells compared to mock-transfected cells (10.6 +- 0.8 muM vs. 0.3 +- 0.004 muM, p = 0.009) and was significantly reduced in SLC22A1-expressing cells when co-incubated with all antiretrovirals tested except atazanavir, lamivudine, tenofovir, zidovudine, and raltegravir.	Tetraethylammonium	0-18	latexin	Homo sapiens	119-122	
25914645-6	2015	Accumulation of tetraethylammonium (5.5 muM, 30 min) was determined in SLC22A1-expressing and mock-transfected cells with and without 50 muM of SLC22A1 inhibitor prazosin, or 50 muM of each antiretroviral drug.	Tetraethylammonium	16-34	latexin	Homo sapiens	40-43	
25914645-9	2015	Tetraethylammonium accumulation was higher in SLC22A1-expressing cells compared to mock-transfected cells (10.6 +- 0.8 muM vs. 0.3 +- 0.004 muM, p = 0.009) and was significantly reduced in SLC22A1-expressing cells when co-incubated with all antiretrovirals tested except atazanavir, lamivudine, tenofovir, zidovudine, and raltegravir.	Tetraethylammonium	0-18	latexin	Homo sapiens	140-143	
16880198-3	2006	This uncharged compound acts with an apparent affinity of 1 muM at the tetraethylammonium (TEA) site at the external mouth of the Kv2.1 channel but is ineffective on Kv1.5.	Tetraethylammonium	71-89	latexin	Homo sapiens	60-63	
16880198-3	2006	This uncharged compound acts with an apparent affinity of 1 muM at the tetraethylammonium (TEA) site at the external mouth of the Kv2.1 channel but is ineffective on Kv1.5.	Tetraethylammonium	91-94	latexin	Homo sapiens	60-63